Literature DB >> 25381443

Thrombin-dependent Incorporation of von Willebrand Factor into a Fibrin Network.

Adam Miszta1, Leonie Pelkmans2, Theo Lindhout2, Ganeshram Krishnamoorthy3, Philip G de Groot4, Coenraad H Hemker2, Johan W M Heemskerk3, Hilde Kelchtermans2, Bas de Laat2.   

Abstract

Attachment of platelets from the circulation onto a growing thrombus is a process involving multiple platelet receptors, endothelial matrix components, and coagulation factors. It has been indicated previously that during a transglutaminase reaction activated factor XIII (FXIIIa) covalently cross-links von Willebrand factor (VWF) to polymerizing fibrin. Bound VWF further recruits and activates platelets via interactions with the platelet receptor complex glycoprotein Ib (GPIb). In the present study we found proof for binding of VWF to a fibrin monomer layer during the process of fibrinogen-to-fibrin conversion in the presence of thrombin, arvin, or a snake venom from Crotalus atrox. Using a domain deletion mutant we demonstrated the involvement of the C domains of VWF in this binding. Substantial binding of VWF to fibrin monomers persisted in the presence of the FXIIIa inhibitor K9-DON, illustrating that cross-linking via factor XIII is not essential for this phenomenon and suggesting the identification of a second mechanism through which VWF multimers incorporate into a fibrin network. Under high shear conditions, platelets were shown to adhere to fibrin only if VWF had been incorporated. In conclusion, our experiments show that the C domains of VWF and the E domain of fibrin monomers are involved in the incorporation of VWF during the polymerization of fibrin and that this incorporation fosters binding and activation of platelets. Fibrin thus is not an inert end product but partakes in further thrombus growth. Our findings help to elucidate the mechanism of thrombus growth and platelet adhesion under conditions of arterial shear rate.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Arvin; Ellipsometry; Fibrin; Fibrinogen; Platelet; Platelet Glycoprotein Ib; Surface Plasmon Resonance (SPR); von Willebrand Factor

Mesh:

Substances:

Year:  2014        PMID: 25381443      PMCID: PMC4276865          DOI: 10.1074/jbc.M114.591677

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  Measurement of whole blood thrombus formation using parallel-plate flow chambers - a practical guide.

Authors:  Roger Van Kruchten; Judith M E M Cosemans; Johan W M Heemskerk
Journal:  Platelets       Date:  2012       Impact factor: 3.862

Review 2.  Mechanisms of fibrin polymerization and clinical implications.

Authors:  John W Weisel; Rustem I Litvinov
Journal:  Blood       Date:  2013-01-10       Impact factor: 22.113

3.  Role of transglutaminases in cuff-induced atherosclerotic lesion formation in femoral arteries of ApoE3 Leiden mice.

Authors:  Hanke L Matlung; Ed VanBavel; Jeroen van den Akker; Carlie J M de Vries; Erik N T P Bakker
Journal:  Atherosclerosis       Date:  2010-08-11       Impact factor: 5.162

4.  Highly reinforced structure of a C-terminal dimerization domain in von Willebrand factor.

Authors:  Yan-Feng Zhou; Timothy A Springer
Journal:  Blood       Date:  2014-01-06       Impact factor: 22.113

5.  Complementary roles of glycoprotein VI and alpha2beta1 integrin in collagen-induced thrombus formation in flowing whole blood ex vivo.

Authors:  Marijke J E Kuijpers; Valerie Schulte; Wolfgang Bergmeier; Theo Lindhout; Cord Brakebusch; Stefan Offermanns; Reinhard Fässler; Johan W M Heemskerk; Bernhard Nieswandt
Journal:  FASEB J       Date:  2003-02-05       Impact factor: 5.191

6.  Sequence and structure relationships within von Willebrand factor.

Authors:  Yan-Feng Zhou; Edward T Eng; Jieqing Zhu; Chafen Lu; Thomas Walz; Timothy A Springer
Journal:  Blood       Date:  2012-04-06       Impact factor: 22.113

7.  Real-time monitoring of melittin-induced pore and tubule formation from supported lipid bilayers and its physiological relevance.

Authors:  Radek Machán; Adam Miszta; Wim Hermens; Martin Hof
Journal:  Chem Phys Lipids       Date:  2009-11-17       Impact factor: 3.329

8.  Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain.

Authors:  Eric G Huizinga; Shizuko Tsuji; Roland A P Romijn; Marion E Schiphorst; Philip G de Groot; Jan J Sixma; Piet Gros
Journal:  Science       Date:  2002-08-16       Impact factor: 47.728

9.  Elimination of coagulation factor XIII from fibrinogen preparations.

Authors:  E L Smith; B Cardinali; L Ping; R A S Ariëns; H Philippou
Journal:  J Thromb Haemost       Date:  2013-05       Impact factor: 5.824

Review 10.  Role of fibrin structure in thrombosis and vascular disease.

Authors:  Amy L Cilia La Corte; Helen Philippou; Robert A S Ariëns
Journal:  Adv Protein Chem Struct Biol       Date:  2011       Impact factor: 3.507

View more
  15 in total

1.  Dissecting stroke for anti-VWF therapeutics.

Authors:  Jing-Fei Dong
Journal:  Blood       Date:  2016-05-12       Impact factor: 22.113

2.  Modulating the rate of fibrin formation and clot structure attenuates microvascular thrombosis in systemic inflammation.

Authors:  Christian Valladolid; Marina Martinez-Vargas; Nitin Sekhar; Fong Lam; Cameron Brown; Timothy Palzkill; Alexander Tischer; Mathew Auton; K Vinod Vijayan; Rolando E Rumbaut; Trung C Nguyen; Miguel A Cruz
Journal:  Blood Adv       Date:  2020-04-14

Review 3.  Fibrin Formation, Structure and Properties.

Authors:  John W Weisel; Rustem I Litvinov
Journal:  Subcell Biochem       Date:  2017

4.  Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis.

Authors:  H M H Spronk; T Padro; J E Siland; J H Prochaska; J Winters; A C van der Wal; J J Posthuma; G Lowe; E d'Alessandro; P Wenzel; D M Coenen; P H Reitsma; W Ruf; R H van Gorp; R R Koenen; T Vajen; N A Alshaikh; A S Wolberg; F L Macrae; N Asquith; J Heemskerk; A Heinzmann; M Moorlag; N Mackman; P van der Meijden; J C M Meijers; M Heestermans; T Renné; S Dólleman; W Chayouâ; R A S Ariëns; C C Baaten; M Nagy; A Kuliopulos; J J Posma; P Harrison; M J Vries; H J G M Crijns; E A M P Dudink; H R Buller; Y M C Henskens; A Själander; S Zwaveling; O Erküner; J W Eikelboom; A Gulpen; F E C M Peeters; J Douxfils; R H Olie; T Baglin; A Leader; U Schotten; B Scaf; H M M van Beusekom; L O Mosnier; L van der Vorm; P Declerck; M Visser; D W J Dippel; V J Strijbis; K Pertiwi; A J Ten Cate-Hoek; H Ten Cate
Journal:  Thromb Haemost       Date:  2018-01-29       Impact factor: 5.249

5.  Dominant role of αIIbβ3 in platelet interactions with cross-linked fibrin fragment D-dimer.

Authors:  Lorena Buitrago; Hina Zafar; Yixiao Zhang; Jihong Li; Thomas Walz; Barry S Coller
Journal:  Blood Adv       Date:  2020-07-14

6.  Von Willebrand factor as a thrombotic and inflammatory mediator in critical illness.

Authors:  William E Plautz; Zachary A Matthay; Marian A Rollins-Raval; Jay S Raval; Lucy Z Kornblith; Matthew D Neal
Journal:  Transfusion       Date:  2020-06-01       Impact factor: 3.157

7.  Structural analysis of ischemic stroke thrombi: histological indications for therapy resistance.

Authors:  Senna Staessens; Frederik Denorme; Olivier Francois; Linda Desender; Tom Dewaele; Peter Vanacker; Hans Deckmyn; Karen Vanhoorelbeke; Tommy Andersson; Simon F De Meyer
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

8.  Implant stability in patients treated with platelet-rich fibrin and bovine bone substitute for alveolar ridge preservation is associated with peripheral blood cells and coagulation factors.

Authors:  Joost E I G Brouwers; Lisa N van der Vorm; Sharon Buis; Rianne Haumann; Avesta Karanzai; Joke Konings; Philip G de Groot; Bas de Laat; Jasper A Remijn
Journal:  Clin Exp Dent Res       Date:  2019-12-06

9.  Thrombin Generation and Atherothrombosis: What Does the Evidence Indicate?

Authors:  Hugo Ten Cate; H Coenraad Hemker
Journal:  J Am Heart Assoc       Date:  2016-08-08       Impact factor: 5.501

10.  Clinical evaluation of Emblica Officinalis Gatertn (Amla) in healthy human subjects: Health benefits and safety results from a randomized, double-blind, crossover placebo-controlled study.

Authors:  Mahendra Parkash Kapoor; Koji Suzuki; Timm Derek; Makoto Ozeki; Tsutomu Okubo
Journal:  Contemp Clin Trials Commun       Date:  2019-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.